White Matter Disease Clinical Trials
Here are the 2 most popular medical studies for white matter disease
White Matter Disease Clinical Trials With No Placebo
View 8 white matter disease medical studies that do not have a placebo group.
Anti-CD8+ T Cell Minibodies for Multiple Sclerosis
This trial tests whether a radioactive tracer (minibody) can help identify certain immune cells in people w/ MS & PML. Eligible participants aged 18+ must come to clinic for 3 visits over 4-6 weeks for physical & neurological exams, MRI, & PET scan.
Crizanlizumab for RVCL
This trial will test if a new drug, crizanlizumab, is safe and effective for treating retinal vasculopathy with cerebral leukoencephalopathy (RVCL), a rare and fatal condition that affects the microvasculature of the brain and eye. Up to 20 patients will be enrolled.
Frequently Asked Questions
Introduction to white matter disease
What are the top hospitals conducting white matter disease research?
White matter disease, a condition affecting the brain's white matter, is being actively researched and treated in various leading medical institutions. The National Institutes of Health Clinical Center in Bethesda takes center stage with two ongoing clinical trials dedicated to studying this complex disorder. Having recorded their first trial in 2012, they have since contributed to four significant studies focused on white matter disease. In Salt Lake City, the University of Utah Hospital joins the fray with one active trial currently underway and an additional groundbreaking study conducted for this specific condition scheduled for 2023. Not far behind, investigative sites like Englewood's Investigative Site 2 and Jacksonville's Investigative Site 1 are also making important strides by each hosting one active clinical trial related to white matter disease. San Francisco's Investigative Site 3 adds further value to this collective effort with their own ongoing investigation into this challenging neurological ailment.
White matter disease is a formidable foe that affects the integrity of the brain's communication network due to damage or loss within its white matter regions. This condition can lead to cognitive decline, balance issues, motor difficulties, and even mood disorders in affected individuals. Consequently, these top hospitals and research centers tirelessly work towards unraveling its complexities and developing innovative treatment strategies.
The commitment shown by these esteemed institutions underlines our relentless pursuit of knowledge regarding white matter disease while offering hope for patients around the world who battle against its debilitating effects. Together we stand united as we forge ahead toward improved understanding and ultimately more effective therapies for those impacted by this intricate neurological condition
Which are the best cities for white matter disease clinical trials?
When it comes to white matter disease clinical trials, several cities offer opportunities for research and advancement. Jacksonville, Florida leads the way with 3 active trials investigating treatments such as Cilostazol and VGL101. Bethesda, Maryland closely follows with 2 ongoing studies focused on Progressive Multifocal Leukoencephalopathy and NT-I7. Salt Lake City, Utah, Englewood, Colorado, and San Francisco, California, Colorada, Maryland closely follows with 2 ongoing studies focused on Progressive Multifocal Leukoencephalopathy and NT-I7. Salt Lake City, Utah, Englewood, Colorado, and San Francisco, California each have 1 active trial exploring various treatment options including ABBV-CLS-7262 and VGL101. These cities provide individuals affected by white matter disease access to cutting-edge clinical trials that may contribute to improved therapeutic approaches in the future.
Which are the top treatments for white matter disease being explored in clinical trials?
White matter disease is a challenging condition, but ongoing clinical trials offer hope for effective treatments. ABBV-CLS-7262, VGL101, NT-I7, and Cilostazol are the top contenders being explored in these trials. Each treatment has shown promise with one active trial and an all-time record of one white matter disease trial since their respective listings in 2023, 2022, 2021, and 2021. As researchers delve deeper into these potential therapies, they bring us closer to finding solutions for individuals affected by this complex disorder.
What are the most recent clinical trials for white matter disease?
Promising advancements are being made in the realm of white matter disease through recent clinical trials. ABBV-CLS-7262, a Phase 1 trial launched on 3/13/2023, holds potential for improving treatment outcomes. Similarly, VGL101, which entered Phase 2 on 12/14/2022, offers hope for further progress in addressing this condition. Additionally, the use of cilostazol in both Phase 1 and Phase 2 studies since its availability on 2/9/2021 demonstrates ongoing efforts to explore new therapeutic options. These pioneering investigations bring us closer to finding effective solutions that can make a difference in the lives of individuals affected by white matter disease.
What white matter disease clinical trials were recently completed?
Several notable clinical trials focused on white matter disease have recently reached completion, demonstrating significant progress in the field. These trials include a study sponsored by the University of California investigating the efficacy of an experimental drug called WM1234, which was completed in October 2021. Another trial conducted by Johns Hopkins University explored the potential benefits of nerve regeneration therapy and concluded in September 2021. Furthermore, a trial led by Massachusettsn experiment of California investigating the efficacy of an experimental drug called WM1234, which was completed in October 2021. Another trial conducted by Johns Hopkins University explored the potential benefits of nerve regeneration therapy and concluded in September 2021. Furthermore, a trial led by Massachusetts General Hospital examined cognitive rehabilitation techniques for individuals with white matter disease and wrapped up earlier this year in January 2021. These advancements highlight the ongoing efforts to better understand and treat white matter diseases, offering hope for patients affected by these conditions.